| 摘要 |
The present invention relates to a pharmaceutical product for administration to a patient, the product comprising 4'-cyano-.alpha.',.alpha.', .alpha.'- trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide , or a pharmaceutically acceptable salt or solvate thereof, in solid dispersio n with an enteric polymer having a pKa from 3 to 6, the product further comprising an anti-oestrogen (eg, tamoxifen citrate) and/or an aromatase inhibitor (eg, anastrozole). The invention also relates to a pharmaceutical dose of the drug and anti-oestrogen/aromatase inhibitor provided by such a formulation. An advantage is the treating and/or preventing of at least one side effect selected from gynaecomastia, breast tenderness, hot flushes, impotence and reduction in libido, while increasing the bioavailability of t he drug; reducing inter-patient variability in plasma concentrations of the 4'- cyano-.alpha.',.alpha.',.alpha.'-trifluoro-3-(4-fluorophenylsulphonyl)-2- hydroxy-2-methylpropiono-m-toluidide; enhancing the storage stability of the drug; and/or treating and/or reducing the risk of prostate cancer in a patie nt.
|
